Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
A wild DMT trip that blasts you off to a different dimension has potential to be therapeutic, but also very anxiety-inducing.
That’s why Cybin (CYBN) developed a version of the molecule that breaks down slowly in the body. So instead of a 10-minute rocket ride to outer space, patients have a smoother, more pleasant experience with a larger therapeutic window.
The company received a patent for the formulation this week and will study it as a treatment for anxiety disorders in Q3 of this year.
